News

Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
Upstate Business Journal2h
The Motley Fool: ADRs, explained
An ADR is created when a bank buys shares of a foreign company outside the United States and issues a security representing shares of that company. Priced in U.S. dollars, these ADR shares trade just ...
Zacks Investment Research on MSN2h
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion
Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...
Bristol Myers tops revenue expectations on strength of older drugs, shares fall
Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...
InvestorsHub on MSN5h
Bristol-Myers Squibb Shares Climb as Growth Portfolio Fuels Strong Q2 Results
Bristol-Myers Squibb (NYSE:BMY) posted second-quarter earnings that surpassed analyst expectations, largely thanks to robust ...
Bristol-Myers delivers double beat and raises full-year sales forecast
Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...
Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations
Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...
Bristol Myers posts better-than-expected second quarter results on strength of top sellers
Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...